CVS Health 340B Lawsuits: What Covered Entities Need to Know

In May 2026, several major health systems—including Mount Sinai Health System, University of Michigan Health, and University of Kansas Health System—filed suit against CVS Health, alleging the company and affiliated entities withheld approximately $250 million in 340B drug discount program savings from covered entities. The cases allege that funds that should have been returned to participating providers were instead retained by CVS-affiliated organizations.

CVS Health has denied the allegations, and the litigation remains ongoing. No court has ruled on the merits of the claims.

What the Lawsuits Allege

At the core of the complaints is an allegation that CVS-affiliated entities retained proceeds associated with 340B discounts rather than passing those savings on to the hospitals and health centers entitled to them under their contractual arrangements.

The 340B program was established in 1992 to allow covered entities—including federally qualified health centers, Ryan White clinics, and safety-net hospitals—to purchase outpatient drugs at significantly reduced prices, generating savings that subsidize care for low-income and uninsured patients.

According to the lawsuits, specialty drug claims were initially reimbursed at one rate and later identified as 340B-eligible. The health systems allege that CVS-affiliated entities then applied lower reimbursement amounts tied to 340B pricing while retaining the difference rather than remitting those funds to participating covered entities as required under their agreements. Across the lawsuits, plaintiffs collectively allege approximately $250 million in diverted savings.

CVS disputes these allegations and has stated that its practices comply with applicable agreements and requirements.

Why This Matters for Covered Entities

Even if your clinic is not among the plaintiffs, the CVS lawsuits spotlight a vulnerability that affects the broader 340B ecosystem: when covered entity revenue flows through a PBM, contract pharmacy administrator, or other intermediary, your savings are only as secure as the underlying contract structure—and your ability to audit it.

Key takeaways for covered entities:

• Audit contract pharmacy and third-party administrator arrangements annually for compliance with 340B pricing pass-through requirements.
• Understand the dispute resolution provisions and audit rights contained in your agreements.
• Diversify how your organization captures and deploys 340B savings where operationally feasible.
• Document patient eligibility, dispensing records, and program oversight activities rigorously to support compliance and audit readiness.
• Regularly review financial reconciliation reports to identify unexplained variances in 340B-related revenue streams.

The PIAP Model as a Structural Safeguard

One strategy that can reduce dependence on certain third-party pharmacy arrangements is a Premium Insurance Assistance Program (PIAP). Rather than relying exclusively on external pharmacy networks to capture 340B-related value, a PIAP uses eligible program savings to help patients obtain and maintain health insurance coverage.

This model can create a positive cycle: covered entities help eligible patients enroll in commercial insurance plans, which may improve access to care while generating reimbursement opportunities that support expanded services. Importantly, organizations pursuing this strategy may reduce their reliance on external parties to account for and distribute program-related revenue.

As the CVS litigation illustrates, the financial value generated through the 340B program can be affected by decisions made at multiple points in the pharmacy and reimbursement supply chain. A PIAP strategy may help covered entities maintain greater visibility into how program-related resources are deployed.

What to Do Now

The CVS litigation may take years to resolve, but the compliance and revenue management lessons are immediate. Whether or not you are directly affected, this is the right moment to review how your organization captures, tracks, and deploys 340B savings — and to explore whether a PIAP structure could create a more durable revenue foundation.

Ready to protect your 340B revenue from external risk? Contact American Exchange to download our one-page PIAP overview and see how covered entities are building more defensible financial models.

Schedule time to meet with our team to discuss.